Latest news with #HikmaFinance
Zawya
5 days ago
- Business
- Zawya
Fitch upgrades Hikma Pharmaceuticals PLC's long-term issuer default rating to ‘BBB', outlook stable
Amman, Jordan – Hikma Pharmaceuticals PLC (Hikma, Company) is pleased to announce that Fitch has upgraded its long-term issuer default rating and the senior unsecured rating on Hikma Finance USA LLC's $500 million notes to 'BBB' from 'BBB-' with a stable outlook. Khalid Nabilsi, CFO of Hikma said: 'I am pleased that now both Fitch and S&P have upgraded Hikma to BBB, reinforcing our investment grade rating. These upgrades are a strong endorsement of our strategic direction, financial discipline, and operational resilience. They underscore Hikma's solid market position across key geographies and reflect confidence in our ability to consistently deliver strong financial results, supported by our diversified business model, robust balance sheet, and prudent capital allocation.' About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, MENA and Europe.
Zawya
5 days ago
- Business
- Zawya
Fitch upgrades Hikma Pharmaceuticals PLC's long-term issuer default rating to ‘BBB'
Amman, Jordan – Hikma Pharmaceuticals PLC (Hikma, Company) is pleased to announce that Fitch has upgraded its long-term issuer default rating and the senior unsecured rating on Hikma Finance USA LLC's $500 million notes to 'BBB' from 'BBB-' with a stable outlook. Khalid Nabilsi, CFO of Hikma said: 'I am pleased that now both Fitch and S&P have upgraded Hikma to BBB, reinforcing our investment grade rating. These upgrades are a strong endorsement of our strategic direction, financial discipline, and operational resilience. They underscore Hikma's solid market position across key geographies and reflect confidence in our ability to consistently deliver strong financial results, supported by our diversified business model, robust balance sheet, and prudent capital allocation.' About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, MENA and Europe. For more information, please visit: *Source: AETOSWire Contacts: Bedour Mossa Email: bmossa@
Zawya
12-05-2025
- Business
- Zawya
Jordan: S&P upgrades Hikma Pharmaceuticals PLC, senior notes to ‘BBB'
AMMAN — S&P has announced on 8 May that it has raised its long-term issuer credit rating on Hikma Pharmaceuticals PLC (Hikma) and its $500 million notes outstanding due on July 9, 2025, issued out of Hikma Finance USA LLC, to 'BBB' from 'BBB-' with a stable outlook. S&P said its rating action reflects Hikma's good business momentum and ability to maintain healthy growth prospects and stable credit metrics, according to a Hikma statement. CFO of Hikma Khalid Nabilsi said: 'I am pleased that S&P have upgraded Hikma, strengthening our investment grade rating and confirming our solid market position as well as our track record of profitability and cash generation.' © Copyright The Jordan Times. All rights reserved. Provided by SyndiGate Media Inc. (
